Literature DB >> 16688386

[Health technology assessment: Critical scientific methods for evaluating the effects of medical interventions].

C Wild1.   

Abstract

In all western countries health care budgets are under considerable constraint and therefore a reflection process has started on how to gain the most health benefit for the population within limited resource boundaries. The field of health technology assessment (HTA) has evolved over the last 15 years in order to bring some objectivity and rationality in the discussion and to evaluate health interventions systematically not only under clinical, but also under economic and organisational perspectives. The research area is internationally well established and is being used increasingly more in Austria and Germany. In this article the method of HTA and its general applications as well its explosive nature are presented.

Mesh:

Year:  2006        PMID: 16688386     DOI: 10.1007/s00101-006-0999-2

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  10 in total

1.  Uneasy alliance--clinical investigators and the pharmaceutical industry.

Authors:  T Bodenheimer
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

2.  Introduction: health technology assessment and the European Union.

Authors:  D Banta; W Oortwijn
Journal:  Int J Technol Assess Health Care       Date:  2000       Impact factor: 2.188

3.  The ethics of assessing health technologies.

Authors:  G J Van der Wilt; R Reuzel; H D Banta
Journal:  Theor Med Bioeth       Date:  2000-01

4.  The uncertainty principle and industry-sponsored research.

Authors:  B Djulbegovic; M Lacevic; A Cantor; K K Fields; C L Bennett; J R Adams; N M Kuderer; G H Lyman
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

Review 5.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors:  Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal:  BMJ       Date:  2003-05-31

6.  [A new measure. New studies require new criteria for critical appraisal].

Authors:  Norbert Donner-Banzhoff; Monika Lelgemann
Journal:  Z Arztl Fortbild Qualitatssich       Date:  2003-07

Review 7.  [Me-too pharmaceuticals -- marketing-strategies of drug producers and drug purchasers. Example: non-ionic contrast media].

Authors:  C Wild; S Puig
Journal:  Gesundheitswesen       Date:  2004-11

Review 8.  Evaluating and planning ICUs: methods and approaches to differentiate between need and demand.

Authors:  Claudia Wild; Markus Narath
Journal:  Health Policy       Date:  2005-03       Impact factor: 2.980

9.  "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada.

Authors:  Steven G Morgan; Kenneth L Bassett; James M Wright; Robert G Evans; Morris L Barer; Patricia A Caetano; Charlyn D Black
Journal:  BMJ       Date:  2005-09-02

10.  [Health policy decisions between rationing and rationalization--exemplified by erythropoietin in tumor anemia].

Authors:  C Wild; S Jonas
Journal:  Gesundheitswesen       Date:  2001-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.